Ascites, Hyponatremia, and Hepatorenal Syndrome: Progress in TreatmentA. L. Gerbes Karger Medical and Scientific Publishers, 2011 - 212 من الصفحات At the cutting edge of pathomechanisms and treatment strategies Ascites is the most frequent and hepatorenal syndrome the most lethal complication in liver cirrhosis. In recent years, major progress has been made regarding effective treatment of these complications, thus reducing mortality in patients. This publication highlights and critically appraises recent achievements and novel advances, and at the same time provides the background needed to grasp novel concepts. Topics treated include complications of paracentesis, the right choice of plasma expanders, and selection of patients who will experience survival benefit from transjugular intrahepatic portosystemic shunt. Hepatorenal syndrome, on the other hand, is responsible for a broad spectrum of manifestations caused by acute kidney injury, which until recently was considered a lethal condition. Drug treatments to improve renal function and prolong survival are therefore also discussed, including important issues for clinical outcome which are still under debate. Moreover, the role of combined kidney-liver transplantation versus conventional liver-only transplantation is addressed, as well as the use of vaptans in hyponatremia and their controversial role in the treatment of ascites. Renowned experts share their knowledge and expertise and provide an international perspective. Their contributions include up-to-date references and a bullet-point summary, making this publication most valuable for practitioners, clinicians and scientists in the field. |
المحتوى
Differential Diagnosis of Ascites | 1 |
Diuretics | 11 |
Paracentesis | 23 |
Which PlasmaExpander? | 32 |
Not Just a Plasma Expander | 40 |
Which Patients WillBenefit? | 52 |
Spontaneous Bacterial Peritonitis Prophylaxis and Treatment | 65 |
Clinical Implications of Hyponatremia inCirrhosis | 83 |
Role of Infections in Hepatorenal Syndrome | 130 |
TIPS for HRS | 142 |
Vasoconstrictor Therapy for HepatorenalSyndrome | 149 |
The US Experience | 163 |
Predictors of Response | 172 |
Safety of Terlipressin for HepatorenalSyndrome | 178 |
Novel Strategies and Future Perspectives | 189 |
Hepatorenal Syndrome and LiverTransplantation | 198 |
Vaptans for Ascites Chances and Risks | 91 |
Cardiorenal Syndrome A New Entity? | 102 |
Renal Failure in Cirrhosis | 112 |
Clinical Consequences | 122 |
طبعات أخرى - عرض جميع المقتطفات
عبارات ومصطلحات مألوفة
abdominal advanced cirrhosis adverse events albumin infusion aldosterone antibiotic Arroyo arterial ascitic fluid bacterial infections bacterial translocation baseline bilirubin bleeding cardiac output chronic cirrhotic patients Clin complications controlled trial decrease diagnosis diuretic dose factors Gastroenterology Gerbes Gines Guevara hemodynamic hepatic encephalopathy Hepatology hepatorenal syndrome hyponatremia hypovolemia improvement increased intrahepatic portosystemic shunt ischemic Karger liver disease liver transplantation MELD score mg/dl midodrine mmol/l mortality Navasa noradrenaline norfloxacin octreotide ornipressin paracentesis patients treated patients with ascites patients with cirrhosis patients with HRS patients with type PICD placebo plasma portal hypertension portosystemic shunt predictors pressure prognosis protein receptor reduced refractory ascites renal dysfunction renal failure renal function renin response risk satavaptan serum creatinine serum sodium side effects splanchnic spontaneous bacterial peritonitis survival systemic terlipressin terlipressin and albumin therapeutic therapy tion TIPS tolvaptan transjugular intrahepatic portosystemic treatment type 1 hepatorenal type 1 HRS vaptans vasoconstrictors vasodilation vasopressin Wong F